Abstract-Although outcome inequalities for non-Hispanic black (NHB) kidney transplant recipients are well documented, there is paucity in data assessing the impact of cardiovascular disease (CVD) risk factors on this disparity in kidney transplantation. Adherence to medications used to manage CVD risk was significantly lower in NHBs. In the fully adjusted models, the independent risk of graft loss in NHBs was substantially reduced (unadjusted hazard ratio, 2.00 versus adjusted hazard ratio, 1.49). CVD risk factors and control reduced the influence of NHB race by 9% to 18%. Similar trends were noted for mortality, and estimates were robust across in sensitivity analyses. These results demonstrate that NHB kidney transplant recipients have significantly higher rates of CVD risk factors and reduced CVD risk control. These issues are likely partly related to medication nonadherence and meaningfully contribute to racial disparities for graft outcomes. 
K idney transplantation is a life-prolonging procedure that substantially improves quality of life in those with endstage renal disease. [1] [2] [3] A recent analysis of the United Network for Organ Sharing registry demonstrated that during the past 25 years, kidney transplantation has led to an estimated 1.37 million life-years saved, when compared with patients remaining on the waiting list. 2 However, because kidney graft survival is significantly shorter in black recipients and graft function is highly correlated with mortality, this survival advantage is likely substantially lower in black recipients. 4 Black kidney transplant recipients have significantly higher rates of acute rejection and graft loss. The average kidney transplant functions just more than a half as long as in a black patient. 5 Despite 40 years of focused research endeavors into this disparity, little has changed in this racial inequality. In 1977, Opelz et al 6 demonstrated a 10% absolute difference in 3-year graft survival rates between black and white recipients (25% versus 35%; P<0.001). In the 2012 Scientific Registry of Transplant Recipients annual report, the graft survival inequity between black and nonblack recipients was 12% at 5 years post transplant. 5 Racial disparities in kidney transplantation have primarily been attributed to biological and immunologic differences leading to higher rejection rates, [7] [8] [9] [10] socioeconomic status disadvantages, 11, 12 reduced access to healthcare, medication nonadherence, 13, 14 and comorbidities. [15] [16] [17] Research focused on reducing the higher acute rejection rates in black transplant recipients has been successful, yet graft loss disparities persist. Black renal transplant recipients have disadvantageous immunologic characteristics placing them at higher risk for graft loss. [18] [19] [20] [21] [22] [23] Therefore, most of the past research trying to eliminate outcome disparities in black patients was focused on reducing acute rejection rates through immunosuppressant pharmacotherapy. 24, 25 The impact of socioeconomic status and medication adherence on racial disparities has been well studied with conflicting results. 12, [26] [27] [28] [29] [30] [31] A potentially significant but understudied factor impacting racial disparities in kidney transplant outcomes is
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September 2016 cardiovascular disease (CVD) and CVD risk factors. In the general population, blacks have a significantly higher prevalence of diabetes mellitus and hypertension, which occur at an earlier age with a more progressive phenotype. [32] [33] [34] [35] [36] [37] Yet studies assessing the impact of CVD risk factors' control on racial disparities in transplantation are limited. 38, 39 Because of this discrepancy in evidence, addressing this area of potential risk is likely to provide strong opportunities to assess modifiable factors that may influence racial disparities in transplant. Thus, the objective of this study was to assess the burden of CVD risk factors and risk control in black renal transplants and determine the influence of CVD risk factors on racial disparities for long-term post-transplant outcomes.
Concise Methods

Study Design and Patients
This was a longitudinal cohort study of national data obtained through developing a unique data set by linking the United States Renal Data System (USRDS) and Veterans Affairs (VA) electronic health records. The study population included veteran recipients of solitary kidneys, transplanted between January 1, 2001, and December 31, 2007 (7 years), with longitudinal follow-up through December 31, 2010. Pediatrics, nonrenal transplant recipients, those that were not non-Hispanic white (NHW) or non-Hispanic black (NHB), transplant events that occurred outside the study time frame and those with graft loss or follow-up <1 year were excluded. After local Institutional Review Board, VA Health Services Research & Development, and USRDS approval, the VA system was queried for eligible kidney transplant recipients using International Classification of Diseases Ninth Revision codes (V42.0 or 996.81) without a history of a liver, heart, lung, pancreas, or intestine transplant. This list of patients was submitted to the USRDS, which linked data through scrambled social security numbers to create the study cohort that contained detailed baseline and clinical follow-up data. Further details regarding the data sources to create this cohort have previously been published. 40 
Outcome Measures
The primary outcome for this analysis was graft loss, which was defined as either a return to chronic dialysis or retransplant. For this outcome, death was considered a competing risk event and accounted for through modeling. The outcome was assessed as a time to event analyses, with the reference time being the date of transplant and the end time being the date of either graft loss (event), death (competing event) or the end of the study period (censored). All-cause mortality was a secondary outcome.
Exposure Measurements
There were 2 primary exposures for this study, race and CVD risk factors and risk control. The study cohort was restricted to 2 racial groups, NHWs and NHBs. Race information was gathered from the USRDS data set and cross-validated with the VA vital records data. CVD risk factors and control were focused on the 3 predominant risks: hypertension, diabetes mellitus, and dyslipidemia. Hypertension was defined as a blood pressure of >140/90 mm Hg or the use of antihypertensive medications. Diabetes mellitus was defined as a hemoglobin A1c of >7% or use of antiglycemic therapy. Dyslipidemia was defined as a low-density lipoprotein (LDL) level of >100 mg/dL, triglyceride level of >150 mg/dL, or use of antilipemic therapy. These were defined based on national standards and guidelines specific to transplant. [41] [42] [43] [44] CVD risk factor control assessment was defined as follows: uncontrolled diabetes mellitus was classified as a mean follow-up A1c of ≥8% (referent group) versus <8% (also assessed A1c of ≥7% versus <7% as well). Uncontrolled hypertension control was classified as a mean follow-up blood pressure (BP) ≥140/90 (referent group) versus BP <140/90 mm Hg. For uncontrolled lipids, patients were classified as a mean follow-up LDL ≥100 mg/dL or triglycerides ≥150 mg/dL (referent group), versus LDL <100 mg/dL and triglycerides <150 mg/dL. Medications to treat CVD comorbidities were grouped according to class, and patients were categorized based on the prescribing of this agent (yes versus no) and their adherence to the therapy. Medication possession ratios were calculated using patient-and medicationspecific sums for days' supply (numerator) divided by total days in the year (denominator) and aggregated by year post transplant, using previously validated algorithms. 45, 46 For modeling, medication possession ratio was averaged for the entire follow-up time and dichotomized as <0.8 versus ≥0.8 to classify patients as adherent versus nonadherent; 0.8 has been well established as a valid cut point to define medication adherence as it correlates with outcomes. 47 Medications were grouped as follows: oral antihyperglycemic agents, insulin, HMG CoA (3-hydroxy-3-methyl-glutaryl-coenzyme A) reductase inhibitors (statins), other antilipid therapy, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, diuretics, and antiplatelet therapies.
Additional covariates that were included in multivariable models included recipient sociodemographics (age, sex, and marital status), recipient comorbidities (history of coronary artery disease/angina, previous transplant, and years on dialysis), donor characteristics (living donor, expanded criteria donor, and donor after cardiac death), immunologic characteristics (human leukocyte antigen mismatches and current panel reactive antibody level), baseline immunosuppression (induction therapy, calcineurin inhibitors, adjunctive agents, and corticosteroids), and post-transplant events (delayed graft function and acute rejection).
Statistical Analysis
Univariate analyses compared baseline variables and clinical outcomes by race (NHBs versus NHWs); assessed the baseline and follow-up prevalence and control of hypertension, diabetes mellitus, and dyslipidemia; and determined CVD medication use and adherence using the χ 2 test, the Student t test, or Mann-Whitney U test, depending on data type and normality assumptions. Multivariable modeling was performed using Cox proportional hazard regression, using the Fine and Gray competing risk model for graft loss to estimate the cumulative incidence function and standard Cox models to estimate the survival function for death. 48 Model assumptions by guest on September 23, 2017 http://hyper.ahajournals.org/ Downloaded from of proportionality of hazard over time and linearity for continuous variables were first tested and confirmed, followed by residual assessments to ensure we used the most appropriate data fit and to identify any potential outliers or influential observations. Sequential forward entry of blocks of variables were added to the model, and at each step, the overall impact of NHB race on the outcome was assessed by comparing the change in β to the previous model. The Akaike information criterion was used to assess and compare models as the goodness-offit measure. Large decreases in the Akaike information criterion after the addition of a block of variables suggested strong influence of that block on explaining the variability associated with the outcome. Covariance between repeated transplants in the same individual was accounted for during modeling to prevent underestimating variance. Sensitivity analyses were conducted to ensure the robustness of the estimates, which included standard Cox regression versus competing risk modeling, varying the entry of variable blocks during sequential modeling, using multiple imputation for missing data and using longitudinal analyses through joint modeling to first estimate individual-level random intercepts and slopes for A1c, BP, and lipid levels, followed by entry of these estimates in Cox models. As a final sensitivity analysis, we also assessed the impact of BP control in means and longitudinal models with and without antihypertensive therapies as covariates. Effect modification was assessed by entering interaction terms in the model, with the primary variables of interest being race, delayed graft function, rejection, and CVD risk factors. All data analyses were conducted using SAS (version 9.4; SAS Institute, Inc, Cary, NC). Statistical significance was defined using 2-sided tests with α set at 0.05.
Results
There were 5757 kidney transplants performed between January 1, 2001, and December 31, 2007 , that met inclusion criteria and were capable of being linked between the VA and USRDS databases. Of these, 382 were excluded for being Hispanic, 112 were excluded for being Asian or other races, 345 were excluded for receiving a transplant outside the time period, and 275 were excluded for having graft loss or followup <1 year post transplant, leaving 4643 eligible for inclusion; 1504 were missing data for at least one variable, leaving 3139 cases with complete data, which included NHWs (66.5%) and NHBs (33.5%; see Figure 1 for the study Consort flow diagram). Baseline sociodemographics, donor criteria, and transplant characteristics are summarized and compared between NHWs versus NHBs in Table 1 . At the time of transplant, NHBs were significantly younger (59.5±10.0 versus 57.5±10.4 years); were less likely to be married (57.3% versus 68.4%); and had differences in the level of education (finished high school and attended college), in the primary cause of endstage renal disease (hypertension, diabetes mellitus, and focal segmental glomerulosclerosis), and in pretransplant comorbidities (coronary artery disease, hypertension, and previous transplant). There were also significant differences between NHBs and NHWs for donor criteria (age, sex, race, less living donors, and more donors after cardiac death), immunologic risks (more human leukocyte antigen mismatches and longer cold ischemic times), baseline immunosuppression, and posttransplant outcomes, particularly death-censored graft loss (NHBs 14.7% versus NHWs 8.0%), acute rejection (NHBs 14.8% versus NHWs 11.4%), and delayed graft function (NHBs 24.0% versus NHWs 11.7%).
The prevalence and control of CVD risk factors at baseline and at 1, 3, and 5 years post transplant significantly differed by race (Table 2) . At baseline, NHBs had a higher prevalence of hypertension (96.4% versus 92.3%) and lower prevalence of dyslipidemia (40.7% versus 46.4%). During post-transplant follow-up, the prevalence of hypertension remained significantly higher in NHBs at 1, 3, and 5 years, whereas the prevalence of diabetes mellitus significantly increased in NHBs, as compared with NHWs. Dyslipidemia prevalence substantially increased in both groups, but always remained higher in NHWs until 5 years post transplant. The baseline and post-transplant control of hypertension, diabetes mellitus, and LDL was significantly better in NHWs versus NHBs at most time points. The use of medication classes to treat CVD risk factors and adherence to these medications also differed by race. NHBs were more likely to be prescribed antihypertensive therapy but, in general, had lower rates of adherence to these therapies. This was also demonstrated for post-transplant insulin therapy. Posttransplant statin prescribing was similar, but adherence to this therapy was lower in NHBs. Figures S1 and S2 in the online-only Data Supplement display the data from Table 2 in graphical format.
The fully adjusted model for the primary outcome of graft loss is displayed in Table 3 , demonstrating that after adjusting for all baseline and follow-up variables, including CVD risk and control, NHB race continued to be a significant risk factor (hazard ratio [HR], 1.49; 1.11-1.99; P=0.0072). The fully adjusted model reduced the risk associated with NHB race by 26%. Beyond race, there were 7 variables that were significant independent predictors of graft loss. This included receiving an expanded criteria donor kidney (HR, 1.39; 1.01-1.91; P=0.0455), receiving and being adherent to angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy (HR, 0.45; 0. 29 Table 4 summarizes the results of the sequential modeling for the primary outcome of graft loss with varied entry of the blocks of variables through iterative processes. The results demonstrate that donor characteristics (−13.4 to −4.2%), immunologic risks (−9.6 to −4.7%), CVD risks and control (−17.5 to −8.7%), and post-transplant events (−5.5 to −0.7%) had the largest impact on reducing the independent risks associated of NHB race on graft loss. CVD risk factors and risk control produced the largest reduction in the model Akaike information criterion, suggesting that including these variables in the model substantially improved the model performance in capturing the variability associated with graft loss by enhancing model goodness of fit. Figure 2 displays the cumulative incidence estimates for graft loss, comparing these curves between NHBs versus NHWs for the unadjusted model ( Figure 2A ) and the fully adjusted model ( Figure 2B ). After full adjustment, the estimated incidence curves significantly converge.
The results for the secondary outcomes of mortality are displayed in Table S1 (full model), Table S2 (sequential modeling), and Figure S3 (unadjusted and fully adjusted survival estimates). The full model for mortality demonstrated that NHB race was a significant protective factor for risk of posttransplant death (HR, 0.75; 0.60-0.94; P=0.0132). Additional independent risk factors for death included not being married, deceased donor, mycophenolate therapy, mTOR (mammalian target of rapamycin) therapy, nonadherence to CVD medications, the presence of diabetes mellitus, and uncontrolled hypertension (Table S1) . Sequential modeling for death demonstrated that sociodemographics (predominantly age) were a significant suppressor, whereas donor characteristics, immunologic risks, and CVD risk factors and control were all significant explanatory variables. Similar to modeling for other outcomes, CVD risk factors and control produced the largest reduction in Akaike information criterion, suggesting it explains a substantial portion of the variability associated with the risk of death after transplant.
Five sensitivity analyses were performed to ensure robustness of the estimates from the modeling. This included varied entry of blocks of variables into the sequential modeling, using standard Cox regression for the outcome of graft loss, modeling random and fixed effects for CVD risk factor control variables through joint modeling, assessing BP control with and without antihypertensives included in the modeling, and using multiple imputation for missing data. The results of these sensitivity analyses demonstrated consistent estimates and trends. The full model for the outcome of graft loss with the imputed missing data (n=4643) is displayed in Table S4 , with the rate of missingness in Table S3 . Race continued to be an independent risk factor for graft loss, and after adjustment, the reduction in risk for NHBs was similar to the analysis using cases with complete data (25.5% versus 27.8%); in the imputed model, similar to the model using cases with complete data, CVD risk factors and CVD risk control had the largest impact on model performance and significantly reduced the independent influence of NHB race on graft loss. In the final sensitivity analysis, the estimated impact of uncontrolled hypertension on graft loss was similar in both longitudinal and means models, with and without the inclusion of 
Discussion
The results of this study demonstrate that NHB transplant recipients have a considerably larger burden of CVD risk factors, which meaningfully contribute to racial disparities in graft outcomes. Specifically, NHBs have a higher prevalence of hypertension and post-transplant diabetes with reduced control of hypertension, diabetes mellitus, and LDL, when compared with NHWs. In addition, adherence to medications used to manage CVD risk factors seems to be significantly lower in NHBs, as compared with NHWs. These data provide novel information to demonstrate that focusing on improving the management of CVD risk factors within kidney transplant recipients offers a promising mechanism to both enhance graft outcomes for the entire population while also potentially impacting racial disparities. To our knowledge, this is the first study to comprehensively assess CVD risk factors and risk control in a large national cohort of contemporary US kidney transplant recipients and specifically assess the impact of CVD risk factors on racial disparities.
Racial disparities for outcomes in kidney transplant recipients have been long standing and well documented, with the literature exposing this issue dating back to the late 1970s, when kidney transplantation was still considered an experimental procedure. Recent evidence suggests that during the past 20 years, the absolute disparity in graft survival has slightly improved. Yet, in relative terms, NHBs are still at substantially higher risk of late graft loss (5 year relative risk of graft loss is 2.2 in living donors and 1.8 in deceased donors, comparing NHBs to NHWs). 49 Some aspects that contribute to this disparity have been well studied. It is clear that NHBs have unique immunologic characteristics that increase their results corroborate these previous findings, in that immunologic risks and donor characteristics continue to be significant explanatory variables for racial disparities.
There is paucity in the research assessing CVD risk factors and risk factor control as a potential cluster of explanatory factors for racial disparities in kidney transplant outcomes. This is despite the fact that these risks are decidedly mutable and that there is strong evidence to suggest these issues drive disparate outcomes in the general nontransplant population with diabetes mellitus and hypertension. 52, 53 Previous single-center studies from our research group has demonstrated similar results, and the data from this analysis further support these findings. 38, 39 Hypertension, diabetes mellitus, and LDL have significantly lower rates of control post transplant in NHBs, as compared with NHWs. This is despite the increased use of antihypertensives in NHBs. The higher rates of medication nonadherence in these patients likely contribute to this issue and represents an opportunity for future interventions designed to improve CVD risk factor control in NHBs. It is interesting to note that our study only included veterans obtaining medications through the VA system. Thus, the issues surrounding access and cost of medications should not be a significant factor leading to medication nonadherence in this population. Other factors, including regimen complexity, health literacy, and self-efficacy, may be producing the higher rates of nonadherence that were seen within NHBs in this study. 53 We focused on graft loss after the first year post transplant, because previous studies have demonstrated that racial disparities in transplantation occur later post transplant and CVD risk factors are most likely to influence these later events.
The prescribing of 2 medication classes, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and statins, demonstrated a substantial protective benefit for graft *Varied entry was conducted using iterative modeling and changing the introduction of the blocks of variables into the model to determine their impact on racial disparities. For all scenarios, race was initially entered into the model (unadjusted risk), followed by entry of blocks of variables that varied across different iterations. loss and death. In our study, only ≈50% to 60% of the population was prescribed angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers at 5 years post transplant, and of these, only 40% to 50% were adherent (medication possession ratio ≥80%). For statins, about three-quarters were prescribed this therapy by 5 years and 40% to 60% were adherent. One could argue that because of the prevailing CVD and CVD risks that are highly correlated with chronic kidney disease, these therapies should be prescribed to nearly all kidney transplant recipients that do not have absolute contraindications. 54 Yet, data from this study and other non-VA national and single-center studies of kidney transplant recipients demonstrate that the utilization of these therapies is on the rise but remains substantially below optimal levels. 55, 56 Given the body of evidence in the general nontransplant population and the inherent CVD risk within the kidney transplant population, these results provide evidence to support future interventional studies designed to optimize utilization and adherence to these therapies in kidney transplant recipients as a mechanism to improve long-term graft and patient outcomes. [54] [55] [56] It is also noteworthy that nonadherence to several medication classes was a significant and independent risk factor for both graft loss and death. This included diuretics, insulin, β-blockers, calcium channel blockers, and antiplatelet therapy. This risk was independent of CVD disease and CVD risk factor control. These results may be a true cause and effect relationship, in that medication nonadherence to these therapies may actually lead to increased rates of graft loss and death or could also be a proxy for other risks that are highly correlated to medication nonadherence and that were not measured as a part of this study. 57 In particular, these include social determinants of health (finances, living conditions, social support), health literacy, and self-efficacy. 58 Thus, further research is needed to ascertain whether nonadherence to these medication classes truly causes increased rates of graft loss and death in kidney transplant recipients.
There are several limitations to this analysis that are worthy of discussion. First, this analysis was confined to a veteran transplant population and the number of female recipients is low. Thus, generalizability of these results to female transplant recipients is not warranted. Using a veteran population also restricts the ability of this analysis to assess the impact of insurance coverage and access to care on outcomes. However, previous studies have demonstrated that racial disparities in kidney transplant recipients are similar in magnitude between VA and non-VA populations, and using VA data will allow us to include numerous clinical variables that are missing or not available from previous studies that solely used the USRDS or Centers for Medicare & Medicaid Services data sets. 28 Therefore, for the purposes of this analysis, which focuses on racial disparities as it relates to CVD risk factor control, the benefits provided by the use of VA data greatly outweigh the limitations of solely focusing on veteran patients.
Another limitation of this analysis is its retrospective design, which may increase the risk for confounding and misclassification, potentially biasing the results. However, because we were able to link 2 databases with unique and overlapping data in a longitudinal format, we dramatically minimized these risks. We validated data elements by comparing them between the 2 databases for accuracy and were able to include the largest number of covariates ever reported in a transplant racial disparities analysis. 40 In addition, retrospectively accurately assessing control of CVD risk factors is a difficult endeavor, and using means during the entire follow-up may not truly capture the time dependency of this exposure. However, using the means does allow for a more straightforward analysis and presentation of the data. To assess if longitudinal analyses improve the primary exposure classification, we also conducted a separate analysis, using a time-varying analysis technique to assess for the fixed and random effects (intercept and trajectory) of the BP, A1c, LDL, and triglycerides on the outcomes. 59 The results of this assessment were similar with respect to direction and magnitude; thus, for ease of display and interpretation, we used the mean values, which seem to be an accurate reflection of CVD risk control. Another limitation with this analysis is that we fail to measure and account for biological and socioeconomic differences between NHB and NHW transplant recipients that may explain some of the disparity. This includes genetic variants that are more prevalent in NHB recipients, including cytochrome P450 3A5 and apolipoprotein L1 and the aforementioned social determinants of health. [60] [61] [62] [63] Although we recognize that there are several limitations with using a veteran data set, the overall objectives of this analysis require the use of longitudinal clinical data that is currently unavailable within any other national data set accessible at this level of comprehension and detail.
Perspectives
In summary, these results demonstrate that NHB kidney transplant recipients have significantly higher rates of CVD risk factors and reduced CVD risk control, as compared with NHWs. These issues may be partly related to medication nonadherence, meaningfully contribute to disparities for graft outcomes within NHBs, and represent a promising area for future interventional studies designed to improve CVD risk factor control as a mechanism to optimize graft outcomes and reduce racial disparities in kidney transplantation. • The results provide new insights demonstrating that disparities in outcomes for black kidney transplant recipients are significantly influenced by cardiovascular disease risk factors and risk factor control; in particular, the treatment and control of hypertension and adherence to medications used to manage this condition affect these disparities.
What Is Relevant?
• Improving the management and control of cardiovascular risk factors, particularly hypertension, is likely to significantly improve outcomes in black kidney transplant recipients and reduce disparities in graft survival rates.
Summary
These results demonstrate that blacl kidney transplant recipients have significantly higher rates of cardiovascular disease risk factors and reduced cardiovascular disease risk control, as compared with whites. These issues may be partly related to medication nonadherence and meaningfully contribute to disparities for graft outcomes. 
Novelty and Significance
